Left ventricular dyskinesia reversed by intravenous nitroglycerin: a manifestation of silent myocardial ischemia

Am J Cardiol. 1986 Aug 15;58(4):38B-42B. doi: 10.1016/0002-9149(86)90408-x.

Abstract

Patients with coronary artery disease (CAD) frequently have left ventricular (LV) wall motion abnormalities in the absence of symptoms. Thirty-one patients with such LV wall motion abnormalities in the absence of symptoms participated in a study of the response of these abnormalities to ascending doses of intravenous nitroglycerin (NTG). In a subgroup of 20 patients the relation between the location of LV wall motion abnormalities and the presence or absence of significant CAD (greater than or equal to 50% diameter reduction), in the vessel supplying the LV region, was assessed. Wall motion improved after intravenous NTG; the ejection fraction increased by 3.7% (mean p less than 0.05) and by 9.4% in the 19 patients who responded. There was no significant increase in heart rate; both LV systolic and end-diastolic pressures decreased minimally (12.5 and 3.5 mm Hg, respectively, p less than 0.05). The ejection fraction response was observed with NTG doses less than or equal to 200 micrograms and no dose-response relation was apparent. In the subgroup subjected to regional wall motion analysis, the presence of dyskinesia was significantly (p = 0.007) associated with the presence of important CAD in a vessel supplying that region. Further, the fact that wall motion improvement after NTG was significantly (p = 0.002) associated supports the concept that silent ischemia results in LV regional wall motion abnormalities, which can be reversed with low dose intravenous NTG.

MeSH terms

  • Adult
  • Aged
  • Blood Pressure / drug effects
  • Cardiac Catheterization
  • Coronary Disease / drug therapy*
  • Coronary Disease / physiopathology
  • Female
  • Heart Rate / drug effects
  • Humans
  • Male
  • Middle Aged
  • Myocardial Contraction / drug effects*
  • Nitroglycerin / administration & dosage
  • Nitroglycerin / therapeutic use*
  • Stroke Volume / drug effects

Substances

  • Nitroglycerin